JPRN-UMIN000021526已完成未知
Phase I study of third-line FOLFIRINOX (oxaliplatin, irinotecan, 5-FU, and leucovorin) unresectable Gem/S-1 refractory pancreatic adenocarcinoma - Phase I study of third-line FOLFIRINOX for pancreatic adenocarcinoma
Osaka Medical Center for Cancer and Cardiovascular Diseases Division of Hepatobiliary and Pancreatic Oncology0 个研究点目标入组 60 人开始时间: 2016年3月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Poorly controlled ascites 2. Patients homozygous for UGT1A1*6 or UGT1A1*28, or double heterozygotes (*6/*28) 3. Active infection 4. Lung fibrosis or intestinal pneumonia detectable on chest X-ray and CT 5. Severe complication (heart disease, cirrhosis, diabetes) 6. Myocardial infarction within 3 months 7. Active synchronous or metachronous malignancy, excluding intramucosal carcinoma 8. Pregnant or lactation women, or women with known or suspected pregnancy 9. Symptomatic brain metastasis 10. history of severe drug allergy 11. Grade 2 or higher peripheral sensory neuropathy 12. Impossible to implant the central venous port 13.Patients who are judged inappropriate for the entry into the study by the investigator
研究者
相似试验
已完成
2 期
Phase II study of modified FOLFIRINOX as first-line for advanced pancreatic canceradvanced pancreatic cancerJPRN-UMIN000015376Gifu University Hospital28
未知
2 期
A phase 2 trial of FOLFIRINOX in patients with previously untreated metastatic pancreatic cancerpreviously untreated pancreatic cancerJPRN-jRCT2080221426Yakult Honsha Co.,Ltd.35
已完成
2 期
Phase II trial of modified FOLFIRINOX (irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin) in patients with untreated metastatic pancreatic canceruntreated metastatic pancreatic cancerJPRN-UMIN000013301Cancer Institute Hospital65
进行中（未招募）
不适用
A phase II study of modified FOLFIRINOX(5-FU/LV, irinotecan and oxaliplatin) as second-line chemotherapy for advanced biliary tract cancer after gemcitabine based chemotherapy failureKCT0004433Gyeongsang National University Hospital34
招募中
不适用
Phase II study of FOLFIRINOX for unresectable pancreatic cancer patients after discontinuation of Pegfilgrastimnresectable pancreatic cancerJPRN-UMIN000028055Kanazawa University Hospital33